All Stories

  1. The Cost of Adrenal Insufficiency in England—Analysis of NHS HES Data
  2. Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?
  3. The impact of radiotherapy on the hypothalamo-pituitary axis: old vs new radiotherapy techniques
  4. A study of acromegaly-associated headache with somatostatin analgesia
  5. Paltusotine, a novel oral somatostatin receptor ligand in the management of acromegaly
  6. Adjuvant Rituximab – exploratory trial in young people with Graves’ disease
  7. ChAdOx1 SARS‐CoV‐2 vaccination: A putative precipitant of adrenal crises
  8. Outcomes of 756 patients with differentiated thyroid cancer and excellent response to treatment: An evidence‐based paradigm for long‐term surveillance strategies
  9. Interpretation of the endocrinology of hospital inpatients
  10. The severity of obstructive sleep apnoea does not
  11. Management of persistent acromegaly following primary therapy: The current landscape in the UK
  12. Performance of the unilateral AV/IVC index in primary hyperaldosteronism subtype prediction: A validation study in a single tertiary centre
  13. Construction of a predictive scoring system as a guide to screening and confirmation of the diagnosis of primary aldosteronism
  14. Is Chemotherapy Implicated in the Development of Hypopituitarism in Childhood Cancer Survivors?
  15. Can We Discharge Dynamically Risk-Stratified Low-Risk (Excellent Response to Treatment) Thyroid Cancer Patients After 5 Years of Follow-Up?
  16. Hypothalamo‐pituitary axis irradiation dose thresholds for development of hypopituitarism in adult‐onset gliomas
  17. Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data
  18. Management of glucocorticoids following adrenalectomy for ACTH-independent Cushing's syndrome
  19. Mortality data from the European Adrenal Insufficiency Registry-Patient characterization and associations
  20. Late-onset X-linked adrenal hypoplasia (DAX-1, NR0B1): two new adult-onset cases from a single center
  21. Endemic goitre and hypothyroidism in an adult female patient dependent on total parenteral nutrition
  22. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study
  23. In Response to: Prednisolone Replacement Therapy Mimics the Circadian Rhythm More Closely than Other Glucocorticoids
  24. Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour
  25. Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity - data from the EU-AIR
  26. Prednisolone is associated with a worse lipid profile than hydrocortisone in patients with adrenal insufficiency
  27. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline
  28. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours
  29. Response to ‘How we define hyponatremia?’
  30. The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure
  31. The diagnosis and management of inpatient hyponatraemia and SIADH
  32. Endocrine sequelae beyond 10 years in survivors of medulloblastoma
  33. The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications
  34. Lanreotide autogel in acromegaly – a decade on
  35. European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy
  36. Atypical Presentation of Riedel’s Thyroiditis: Multifocal Nodular Fibrosis and Resolution with Levothyroxine
  37. Serum vascular endothelial growth factor (VEGF) is elevated in GH deficient adults
  38. Partial Growth Hormone Deficiency is Associated With an Adverse Cardiovascular Risk Profile and Increased Carotid Intima-Medial Thickness.
  39. Current therapy and drug pipeline for the treatment of patients with acromegaly
  40. GH sensitivity of GH-deficient adults is dependent on gender but not timing of onset
  41. Hypogonadotropic hypogonadism: a consequence of Chiari-I malformation
  42. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
  43. Resolution of secondary amenorrhoea following withdrawal of dihydocodeine
  44. The Diagnosis of Partial Growth Hormone Deficiency in Adults with a Putative Insult to the Hypothalamo-Pituitary Axis
  45. The Impact of Short-Term Fasting on the Dynamics of 24-Hour Growth Hormone (GH) Secretion in Patients with Severe Radiation-Induced GH Deficiency
  46. A Densitometric and Morphometric Analysis of the Skeleton in Adults with Varying Degrees of Growth Hormone Deficiency
  47. Quality of Life in Adult Growth Hormone Deficiency
  48. The Phenotype of Adults with Partial Growth Hormone Deficiency
  49. Insulin sensitivity is impaired in adults with varying degrees of GH deficiency
  50. Impact of Growth Hormone Status on Body Composition and the Skeleton
  51. Central and peripheral actions of somatostatin on the growth hormone–IGF-I axis
  52. The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion
  53. Growth Hormone Replacement Decreases Plasma Levels of Matrix Metalloproteinases (2 and 9) and Vascular Endothelial Growth Factor in Growth Hormone-Deficient Individuals
  54. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status
  55. Adults with Partial Growth Hormone Deficiency Have an Adverse Body Composition
  56. Low Bone Mass Is an Infrequent Feature of the Adult Growth Hormone Deficiency Syndrome in Middle-Age Adults and the Elderly
  57. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis
  58. Adult growth hormone replacement: current understanding
  59. Plasma total homocysteine concentrations in adults with growth hormone (GH) deficiency: effects of GH replacement
  60. Adult Growth Hormone Replacement: Lessons Learned and Future Direction
  61. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults
  62. Timing of onset of growth hormone deficiency is a major influence on insulin-like growth factor I status in adult life
  63. Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in Type II diabetes
  64. Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome
  65. Spinal irradiation impairs the osteo-anabolic effects of low-dose GH replacement in adults with childhood-onset GH deficiency
  66. Differential Effects of GH Replacement on the Components of the Leptin System in GH-Deficient Individuals
  67. GH-Deficient Survivors of Childhood Cancer: GH Replacement during Adult Life
  68. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients
  69. Survivors of child-hood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance.
  70. Growth hormone: current and future therapeutic applications
  71. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency
  72. Clinical presentation of PCOS following development of an insulinoma: Case Report
  73. Survivors of childhood cancer: long-term edocrine and metabolic problems dwarf the growth distrubance
  74. Influences on quality of life in GH deficient adults and their effect on response to treatment
  75. Gonadotrophin-releasing hormone analogues: a novel treatment for premenstrual asthma
  76. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults